NCT02326441View on ClinicalTrials.gov

Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies

PHASE1CompletedINTERVENTIONAL

Enrollment

29

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 31, 2017

Study Completion Date

May 23, 2018

Conditions

Advance Malignancies

Interventions

DRUG

KX2-361

Trial Locations (3)

14263

Roswell Park Cancer Institute, Buffalo

44195

Cleveland Clinic, Taussig Cancer Institute, Cleveland

78229

UTHSCSA Cancer Therapy and Research Center, San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Athenex, Inc.

INDUSTRY